These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17326278)

  • 41. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.
    Dowell JA; Schranz J; Baruch A; Foster G
    J Clin Pharmacol; 2005 Dec; 45(12):1373-82. PubMed ID: 16291712
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Liver failure in a child receiving highly active antiretroviral therapy and voriconazole.
    Scherpbier HJ; Hilhorst MI; Kuijpers TW
    Clin Infect Dis; 2003 Sep; 37(6):828-30. PubMed ID: 12955645
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients.
    Kulemann V; Bauer M; Graninger W; Joukhadar C
    Pharmacology; 2005 Dec; 75(4):165-78. PubMed ID: 16192747
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Voriconazole-associated severe hyponatremia.
    Kim KH; Lee S; Lee S; Yun NR; Kim NJ; Yu KS; Jang IJ; Park WB; Oh MD
    Med Mycol; 2012 Jan; 50(1):103-5. PubMed ID: 21671829
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Photosensitivity in immunocompromised patients receiving long-term therapy with oral voriconazole.
    Frick MA; Soler-Palacín P; Martín Nalda A; Guarner ME; Nadal CF
    Pediatr Infect Dis J; 2010 May; 29(5):480-1. PubMed ID: 20431387
    [No Abstract]   [Full Text] [Related]  

  • 46. Voriconazole-associated phototoxic effects and lentigo formation in an African American man.
    Elbaum DJ; Cowen EW
    Arch Dermatol; 2012 Aug; 148(8):965-6. PubMed ID: 22911208
    [No Abstract]   [Full Text] [Related]  

  • 47. Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population.
    Imataki O; Ohnishi H; Kitanaka A; Kubota Y; Ishida T; Tanaka T
    Int J Hematol; 2008 Jul; 88(1):3-6. PubMed ID: 18574651
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis.
    Kobayashi K; Kami M; Murashige N; Kishi Y; Fujisaki G; Mitamura T
    Haematologica; 2004 Nov; 89(11):ECR42. PubMed ID: 15533847
    [No Abstract]   [Full Text] [Related]  

  • 49. Voriconazole-induced pancreatitis in a patient of acute myeloid leukemia and invasive aspergillosis.
    Philip A; Sivaprakasam P; Sagar TG; Ganesan P
    J Pediatr Hematol Oncol; 2012 Jul; 34(5):406. PubMed ID: 22713708
    [No Abstract]   [Full Text] [Related]  

  • 50. [A suspected case of voriconazole-induced lung injury].
    Ishikawa S; Yano S; Tokuda Y; Wakabayashi K; Kobayashi K; Ikeda T; Takeyama H
    Nihon Kokyuki Gakkai Zasshi; 2008 Apr; 46(4):319-24. PubMed ID: 18516997
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Severe acute hypokalaemia secondary to voriconazole. Uncommon pharmacological causes of hypokalaemia.
    González Rozas M; Alvarez Tundidor S; Pineda Alonso M
    Nefrologia; 2011; 31(1):112-3. PubMed ID: 21270925
    [No Abstract]   [Full Text] [Related]  

  • 52. High frequency of voriconazole-related phototoxicity in cystic fibrosis patients.
    Rondeau S; Couderc L; Dominique S; Pramil S; Leguillon C; Masseline B; Favennec L; Marguet C
    Eur Respir J; 2012 Mar; 39(3):782-4. PubMed ID: 22379155
    [No Abstract]   [Full Text] [Related]  

  • 53. Voriconazole in the treatment of invasive fungal infections.
    Keady S; Thacker M
    Intensive Crit Care Nurs; 2005 Dec; 21(6):370-3. PubMed ID: 15985371
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole.
    Ullmann AJ
    Curr Med Res Opin; 2003; 19(4):263-71. PubMed ID: 12841918
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy.
    McCarthy KL; Playford EG; Looke DF; Whitby M
    Clin Infect Dis; 2007 Mar; 44(5):e55-6. PubMed ID: 17278050
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Voriconazole-associated visual disturbances and hallucinations.
    Bayhan GI; Garipardic M; Karaman K; Akbayram S
    Cutan Ocul Toxicol; 2016 Mar; 35(1):80-2. PubMed ID: 25799212
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phototoxic dermatoses in pediatric BMT patients receiving voriconazole.
    Goyal RK; Gehris RP; Howrie D; Cogley KM; Windreich RM; Venkataramanan R
    Pediatr Blood Cancer; 2014 Jul; 61(7):1325-8. PubMed ID: 24619922
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pseudoporphyria induced by voriconazole.
    Sharp MT; Horn TD
    J Am Acad Dermatol; 2005 Aug; 53(2):341-5. PubMed ID: 16021136
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic drug monitoring of voriconazole and posaconazole.
    Hussaini T; Rüping MJ; Farowski F; Vehreschild JJ; Cornely OA
    Pharmacotherapy; 2011 Feb; 31(2):214-25. PubMed ID: 21275497
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms.
    Levin MD; den Hollander JG; van der Holt B; Rijnders BJ; van Vliet M; Sonneveld P; van Schaik RH
    J Antimicrob Chemother; 2007 Nov; 60(5):1104-7. PubMed ID: 17827141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.